

# Christopher Coyle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5773150/publications.pdf>

Version: 2024-02-01

10  
papers

338  
citations

1478505

6  
h-index

1588992

8  
g-index

11  
all docs

11  
docs citations

11  
times ranked

770  
citing authors

#	ARTICLE	IF	CITATIONS
1	What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients. <i>Gynecologic Oncology</i> , 2018, 148, 254-257.	1.4	37
2	Emergency etoposide-cisplatin (Em-EP) for patients with germ cell tumors (GCT) and trophoblastic neoplasia (TN).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16539-e16539.	1.6	0
3	Repurposing Vitamin D as an Anticancer Drug. <i>Clinical Oncology</i> , 2016, 28, 36-41.	1.4	14
4	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. <i>Contemporary Clinical Trials</i> , 2016, 51, 56-64.	1.8	129
5	Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 27-34.	0.5	45
6	Erythema nodosum as a result of estrogen patch therapy for prostate cancer: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 285.	0.8	1
7	PROMIS " Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. <i>Contemporary Clinical Trials</i> , 2015, 42, 26-40.	1.8	89
8	Diagnostic Criteria Schemes for Multicentric Castleman Disease in 75 Cases. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, e80-e82.	2.1	21
9	Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1617-TPS1617.	1.6	2
10	A new differential for pyrexia of unknown origin?. <i>Clinical Medicine</i> , 2008, 8, 230.2-230.	1.9	0